

Real time, ultra fast breath ammonia determination



T.B. Schwartz,¹ S.F. Solga,^{1,2} L. Spacek,² Rafal Lewicki,³ F.K. Tittel,³ and T.H. Risby²




1 – St. Luke's Hospital, Bethlehem, PA, 18015, USA 2 – Johns Hopkins University, Baltimore, MD, 21205, USA 3 – Rice University, Houston, TX, 77251, USA Industry/practitioner collaborators: Loccioni, Hamamatsu

Total many and the standard pairs and the sta

Sinhaholden:

I. INTRODUCTION

Elevated ammonia (NH₃), a ubiquitous by-product of protein metabolism, is thought to be a key pathogenic factor in hepatic encephalopathy (HE), a common and serious disorder associated with liver cirrhosis. The diagnosis and optimal treatment of HE is often cumbersome, and is greatly hindered by the lack of a reliable, quick, and inexpensive surrogate endpoint for clinical improvement. Though it is ordered routinely in clinical practice, blood NH₃ is widely recognized to correlate poorly with HE. We hypothesize that breath NH₃ will be a robust biomarker for the study of whole body NH₃, and that a real-time monitor for breath NH₃ will improve the diagnosis and management of HE.



¹Lewicki, R et al. "Real time ammonia detection in exhaled human breath using a distributed feedback quantum cascade laser based sensor," Proceedings of the SPIE, Quantum Sensing and Nanophotonic Devices VIII, Vol. 7945.

II. METHODS


We used a distributed feedback quantum cascade laser based sensor¹ to determine exhaled breath NH₃ in participants without signs of liver and kidney disease. Blood NH₃ was measured by a standard clinical assay. Pressure and carbon dioxide were measured to ensure careful breath sampling. Statistical analyses were preformed using SAS version 9.1.3. Paired data were compared by linear regression including slope, intercept, and correlation coefficient.

IV. CONCLUSION

Breath $\mathrm{NH_3}$ correlates with the present standard $\mathrm{NH_3}$ blood assay. This work creates a foundation of normative data among healthy subjects. Currently, we are conducting investigations of cirrhotic patients with elevated $\mathrm{NH_3}$ and treatment intervention studies to evaluate the performance of breath $\mathrm{NH_3}$ over a broader range of values and clinical scenarios.

III. RESULTS

Twenty-four participants provided fasting breath (x3) and blood (x1) samples. We used the mean of 3 breath samples to calculate mean breath NH₃ of 0.387 ppm (SD, 0.290; range 0.014-1.089). Mean blood NH₃ was 6.4 µmol/l (SD, 4.4; range 1-14). Five participants had undetectable blood NH₃ levels. For the remaining 19 paired data points, linear regression slope was 0.03 and intercept was 0.20 with Pearson correlation coefficient of 0.47 (p=0.042). R² was 0.22. Graph includes 95% confidence interval.





This material is based upon work supported by the National Science Foundation under Grant No. EEC-0540832